Metyrapone
| Clinical data | |
|---|---|
| Trade names | Metopirone | 
| AHFS/Drugs.com | Consumer Drug Information | 
| Pregnancy category | 
 | 
| Routes of administration | By mouth | 
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 1.9 ± 0.7 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.188 | 
| Chemical and physical data | |
| Formula | C14H14N2O | 
| Molar mass | 226.279 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Metyrapone, sold under the brand name Metopirone, is a medication which is used in the diagnosis of adrenal insufficiency and occasionally in the treatment of Cushing's syndrome (hypercortisolism). It is part of the steroidogenesis inhibitor class of drugs.